{"filings":[{"id":481836,"accession_number":"0001628280-26-035793","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-05-18T10:47:00+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Context Therapeutics buys out future milestones and royalties for CT-202 from BioAtla for $6.5M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid $4.5M upfront and $2M due by Aug 1, 2026 to eliminate all future milestone/royalty obligations.","License becomes irrevocable, royalty-free, fully paid-up, and non-terminable.","BioAtla no longer entitled to future milestones or royalties for CT-202.","Phase 1 trial initiation for CT-202 expected in Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96135,"accession_number":"0001628280-26-029323","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Context Therapeutics resolves stockholder class action; $850K mootness fee paid by third party","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Delaware court invalidated classified board and for-cause removal provisions from charter.","Third-party service provider agreed to pay $850,000 mootness fee; company did not pay.","Fee paid May 1, 2026; action to close after annual meeting scheduled June 24, 2026.","Stipulated order granted April 30, 2026; court retains jurisdiction only for mootness fee application."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96134,"accession_number":"0001628280-26-022931","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics receives FDA Fast Track for CTIM-76 in platinum-resistant ovarian cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation for CTIM-76 (CLDN6 x CD3 bispecific antibody) in PROC after all standard therapies.","Phase 1a trial evaluating CTIM-76 in CLDN6-positive ovarian, endometrial, and testicular cancers is ongoing.","Interim data from the Phase 1a trial expected in June 2026.","Fast Track aims to expedite development and review for serious conditions with unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109768,"accession_number":"0001628280-26-020517","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics releases updated corporate presentation focused on T cell engagers for solid tumors","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation updated March 23, 2026 for investor and analyst meetings.","Slides emphasize advancing T cell engager platform for solid tumors; no financial or clinical data disclosed.","Slides 15 and 32 incorporated into Item 8.01, but specific content not detailed in filing.","Previous presentation replaced; no new pipeline milestones, partnerships, or financing announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109767,"accession_number":"0001628280-26-017691","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Context Therapeutics removes classified board and for-cause removal after court-approved settlement","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court approved stipulation invalidating 3-year director terms and for-cause removal provisions from charter.","Certificate of Correction filed with Delaware Secretary of State on March 11, 2026.","Directors' terms expire at 2026 annual meeting; directors can be removed with or without cause by majority vote.","Stockholder class action dismissed with prejudice as to plaintiff; court retains jurisdiction over mootness fee.","2026 annual meeting set for June 24, 2026; record date April 27, 2026; nominees will serve one-year terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109766,"accession_number":"0001628280-26-012813","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Context Therapeutics settles governance lawsuit; annual director elections June 24, 2026","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Stipulated consent judgment filed Feb 24 invalidates three-year director terms and for-cause removal from charter.","Class action by Vladimir Gusinsky Revocable Trust will be dismissed with prejudice; charter corrected if court approves.","Annual meeting set for June 24, 2026; record date April 27, 2026; agenda includes election of directors to one-year terms.","Stockholder proposals and director nominations due by March 14, 2026; universal proxy notices due by April 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109765,"accession_number":"0001628280-26-001275","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Context Therapeutics files updated corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing updates corporate presentation for investor meetings; presentation content not included in this 8-K.","No financial results, pipeline updates, or guidance changes announced.","Event is a routine FD disclosure; no material impact expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126299,"accession_number":"0001628280-25-049604","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics Q3 net loss $9.7M; early clinical data for CTIM-76 and CT-95","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 net loss $9.7M, down from $17.5M YoY; cash $76.9M sufficient into 2027.","CTIM-76 Phase 1: 12 patients; RECIST response observed from Cohort 3; no CRS>Grade1, no DLT.","CT-95 Phase 1: 6 patients; approaching target dose with Cohort 4; no CRS>Grade2.","CT-202 (Nectin-4 x CD3) preclinical; expects regulatory filing for first-in-human trial in Q2 2026.","Anticipates updated CTIM-76 Phase 1a data and Phase 1b dose selection in Q2 2026; CT-95 data mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126298,"accession_number":"0001628280-25-046258","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics amends ATM agreement to increase offering capacity to up to $75M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prior ATM: sold 14.7M shares for ~$15M through Dec 2, 2024 to Oct 24, 2025.","Amendment raises aggregate offering to $75M (excl. prior sales) under new S-3 effective Nov 14, 2024.","New prospectus supplement dated Oct 24, 2025; agent Leerink commission up to 3% of gross proceeds.","Proceeds intended for R&D, working capital, and general corporate purposes.","Prior ATM prospectus terminated; no further sales under that facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126297,"accession_number":"0001628280-25-045513","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Context Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Oct 17, 2025 confirming compliance regained after 10 consecutive business days with closing bid price at or above $1.00.","Company had been noncompliant since Feb 27, 2025; granted extension to Feb 23, 2026.","Nasdaq considers the matter closed; delisting risk removed.","Stock ticker CNTX trades on Nasdaq under Minimum Bid Price Rule 5550(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143048,"accession_number":"0001842952-25-000085","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Context Therapeutics receives Nasdaq extension until Feb 23, 2026 for bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq extension letter on Aug 28, 2025; new compliance deadline Feb 23, 2026.","Originally notified of non-compliance on Feb 27, 2025; need $1.00 closing bid for 30 consecutive days.","Company may consider reverse stock split to regain bid price compliance.","Listing and trading of CNTX common stock unaffected by extension letter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161160,"accession_number":"0001842952-25-000072","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Context Therapeutics stockholders approve reverse stock split and ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["66,716,026 shares (74.37% of outstanding) present at June 12, 2025 annual meeting.","Ratified CohnReznick LLP as auditor for FY2025 with 66,649,293 votes for, 20,039 against.","Approved reverse stock split at ratio from 1:5 to 1:50, as determined by Board; 65,141,783 for, 1,540,542 against.","No broker non-votes reported; both proposals were routine matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161159,"accession_number":"0001842952-25-000051","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics updates corporate presentation for June 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company issued an updated corporate presentation dated June 2025.","Presentation emphasizes T cell engager platform for solid tumors.","Slide 17 of the presentation is incorporated by reference under Item 8.01.","No clinical data, financial results, or guidance were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161158,"accession_number":"0001842952-25-000037","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics doses first patient in Phase 1 trial of CT-95 bispecific antibody","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody targeting MSLN-expressing cancers.","Second TCE bispecific to enter clinic in 2025 following CTIM-76 (Claudin 6 x CD3) earlier this year.","Phase 1 open-label dose escalation and expansion study for advanced solid tumors (ovarian, pancreatic, lung, mesothelioma).","Initial data for CT-95 Phase 1 trial expected in mid-2026.","CEO Martin Lehr highlights expansion of clinical pipeline and leadership in TCE therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179323,"accession_number":"0001842952-25-000024","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Context Therapeutics receives Nasdaq minimum bid price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Feb 27, 2025 for failing $1.00 minimum bid price for 30 consecutive business days.","Initial 180-day cure period runs until August 26, 2025 to regain compliance.","Must have closing bid price of $1.00+ for at least 10 consecutive business days to cure.","Company will monitor and evaluate options, but no assurance of regaining compliance.","If not cured by Aug 26, may be eligible for an additional 180-day grace period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179322,"accession_number":"0001842952-25-000006","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics doses first patient in Phase 1 trial of CTIM-76 for CLDN6-positive cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1 open-label trial of CTIM-76 (CLDN6 x CD3 bispecific antibody).","Trial targets CLDN6-positive advanced/metastatic ovarian, endometrial, and testicular cancers.","Study expected to enroll up to 70 patients; initial data anticipated first half of 2026.","CEO Martin Lehr highlights the milestone as key pipeline advancement.","Company presented at SITC 2024 supporting first-in-human dose selection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179321,"accession_number":"0001842952-25-000003","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Context Therapeutics appoints Andy Pasternak as Chairman; Richard Berman resigns from Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Berman resigned from Board effective Jan 12, 2025; not due to any disagreement with the Company.","Andy Pasternak appointed Chairman effective Jan 13, 2025; term through 2027 annual meeting.","Pasternak also appointed to Audit and Compensation Committees; Dr. Karen L. Smith named Compensation Committee Chair.","Pasternak granted options to purchase 20,685 shares, vesting by June 13, 2025 or 2025 annual meeting; receives $55K annual cash retainer.","Pasternak brings 25+ years pharma experience, including role in $28B Horizon-Amgen acquisition and Bain Healthcare leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195998,"accession_number":"0001842952-24-000087","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Context Therapeutics sells 14.7M shares for ~$15M to MPM BioImpact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 14,705,882 shares at ~$1.02/share for aggregate gross proceeds of ~$15M.","Shares purchased by MPM BioImpact LLC under sales agreement with Leerink Partners dated Dec 2, 2024.","Proceeds expected to fund working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195997,"accession_number":"0001628280-24-049570","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics enters $75M at-the-market equity offering with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM facility allows sale of up to $75M of common stock from time to time.","Leerink Partners receives 3.0% commission on gross proceeds; company reimburses certain expenses.","Net proceeds to fund R&D of product candidates and working capital / general corporate purposes.","Shares offered under effective S-3 filed Nov 2022; prospectus supplement dated Dec 2, 2024.","Company not obligated to sell any shares; agreement terminates upon full sale or earlier termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212266,"accession_number":"0001842952-24-000083","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics licenses Nectin-4 x CD3 TCE bispecific from BioAtla for up to $133.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$15M upfront/near-term plus up to $118.5M milestones and tiered royalties on net sales.","CT-202 (formerly BA3362) IND filing expected mid-2026; Context to fund all development.","Cash runway into 2027 covering CTIM-76 and CT-95 Phase 1 trials plus CT-202 IND expenses.","First CTIM-76 patient dosing expected Oct/Nov 2024; initial dose escalation data 1H 2026.","CT-95 Phase 1 initial dose escalation data expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212265,"accession_number":"0001842952-24-000081","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Context Therapeutics stockholders approve doubling authorized shares to 200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted 42,389,461 for, 790,853 against, 71,655 abstain to increase authorized common shares to 200,000,000.","Authorization increased from 100,000,000 to 200,000,000 shares of common stock.","Special Meeting held September 17, 2024; quorum of 43,251,969 shares (57.67%) present.","Proposal also included approval of adjournments if needed, passed with 42,447,035 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212264,"accession_number":"0001842952-24-000070","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Context Therapeutics appoints Dr. Karen Smith and Dr. Luke Walker to Board; board expands to 7 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 5 to 7; Dr. Smith (former CMO of Jazz Pharmaceuticals) and Dr. Walker (former CMO of Harpoon Therapeutics) join.","Dr. Smith assigned to Compensation Committee; Dr. Walker to Nominating Committee; both deemed independent under Nasdaq rules.","Each new director received option to purchase 19,315 shares, vesting on earlier of June 13, 2025 or 2025 annual meeting.","Dr. Smith brings over 20 years of oncology drug development (Herceptin, Vyxeos) and regulatory experience; Dr. Walker led Tukysa (tucatinib) development at Seagen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212263,"accession_number":"0001842952-24-000050","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Context Therapeutics acquires CT-95 (mesothelin x CD3 T cell engager) for $3.75M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired CT-95 from Link (assignment for benefit of creditors) for $3.75M upfront payment.","CT-95 is IND-cleared; Phase 1 trial expected to initiate in Q1 2025.","Targets mesothelin, prevalent in ovarian, lung, and pancreatic cancers.","Advancement through Phase 1 dose escalation to be funded with existing cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231186,"accession_number":"0001842952-24-000041","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Context Therapeutics Stockholders Ratify Auditor and Elect Directors at Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ratified CohnReznick LLP as auditor for 2024 with 8,364,879 votes for, 117,835 against.","Elected directors Richard Berman, Dr. Philip Kantoff, Martin Lehr, Jennifer Evans Stacey, Linda West to board.","Director Martin Lehr received highest votes for (6,637,406), Richard Berman lowest (4,774,152).","Proxies represented 53.15% of outstanding shares (8,486,458 votes) out of 15,966,053 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231185,"accession_number":"0001842952-24-000033","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics raises ~$100M via private placement; FDA clears IND for CTIM-76","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement raises ~$100M gross via 64.5M shares/pre-funded warrants at $1.55/share.","FDA cleared IND for CTIM-76 (CLDN6 x CD3 bispecific) for Phase 1 in CLDN6-positive gynecologic/testicular cancers.","First patient enrollment for dose escalation expected mid-2024; Phase 1 study to enroll up to 70 patients.","Proceeds plus existing cash extend cash runway into 2028, covering estimated Phase 1 trial duration.","Private placement led by Nextech, with participation from Ally Bridge, Avidity, Blackstone, Blue Owl, etc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231184,"accession_number":"0001842952-24-000022","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Context Therapeutics submits IND for CTIM-76 Phase 1 trial in CLDN6-positive cancers","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["IND filed March 28, 2024 with FDA for CTIM-76, a CLDN6 x CD3 bispecific antibody.","Phase 1 dose escalation/expansion trial planned in CLDN6-positive gynecologic and testicular cancers.","CEO Martin Lehr calls IND submission a significant milestone for the company.","Company set aggressive 2021 timeline and prioritized CTIM-76 as potentially best-in-class therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249570,"accession_number":"0001842952-24-000010","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Context Therapeutics amends bylaws to reduce quorum to one-third, update proxy rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum reduced to one-third of outstanding shares entitled to vote, effective immediately.","Stockholder list at meetings no longer required; notice rules for director nominations updated.","Proxies soliciting under Rule 14a-19 must certify compliance and provide evidence 5 days before meeting.","Non-compliant nominations deemed void; white proxy cards reserved for Board of Directors only.","Technical, clarifying and conforming changes also adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249569,"accession_number":"0001842952-24-000005","cik":1842952,"company_name":"Context Therapeutics Inc.","ticker":"CNTX","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Context Therapeutics amends Integral license for CTIM-76 after finding potential third-party patent conflict","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discovered third-party patents expiring Jan 2034 may cover CTIM-76; company believes it has defenses but may not prevail.","Amendment reduces development milestones from $55M to $15M, sales milestones from $130M to $12.5M.","Royalty reduced from 8–12% to flat 6% on net sales, starting no sooner than February 2034.","License narrowed to only CTIM-76; company no longer obligated to reimburse Integral for research funding.","Deal includes mutual releases and revised milestone triggers tied to Phase 1b/2, Phase 3, and marketing approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":261396271.49161077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}